Gustave Roussy Immune Score in Nivolumab Treated Metastatic Renal Cell Carcinoma

Aim: The aim of this study is to evaluate the Gustave Roussy immune (GRIm) score as a biomarker for survival in metastatic renal cell carcinoma (mRCC) patients receiving nivolumab following first-line treatment. Material and Method: 41 mRCC patients who were given nivolumab beyond first line were included in this retrospective study. Data on ratio of neutrophile to lymphocyte, albumin, and LDH levels were utilized to determine GRIm score. Patients scoring 2–3 were grouped into the high GRIm score, whereas those scoring 0–1 were grouped as the low GRIm score. The association between the GRIm score and progression-free survival (PFS) with overall survival (OS) was examined. Results: Thirty patients exhibited a low GRIm score, whereas eleven presented a high GRIm score. Prolonged median PFS and OS, with values of 7.06 months compared to 2.89 months (p=0.002) and 20.34 months compared to 4.27 months (p<0.001), are found respectively in low GRIm score group. In terms of PFS, a higher GRIm score was identified as an independent prognostic indicator but lacked prognostic significance for OS in multivariable analysis. Conclusion: The GRIm score may be used as an accessable and cost-effective prognostic biomarker in mRCC patients receiving nivolumab, and may assist clinicians in patient selection, thus improving therapeutic efficacy and the efficient use of clinical resources.